4.8 Article

Tri-stimuli-responsive biodegradable theranostics for mild hyperthermia enhanced chemotherapy

期刊

BIOMATERIALS
卷 126, 期 -, 页码 39-48

出版社

ELSEVIER SCI LTD
DOI: 10.1016/j.biomaterials.2017.02.025

关键词

Tri-stimuli-responsive; Theranostics; Mild hyperthermia; Enhanced chemotherapy; CuS; Periodic mesoporous organosilicas

资金

  1. National Key Basic Research Program of the PRC [2014CB744504, 2014CB744501]
  2. Major International (Regional) Joint Research Program of China [81120108013]
  3. National Natural Science Foundation of China [81201175, 81530054, 81401465, 51573096]
  4. Natural Science Foundation of Jiangsu Province [BK20130863]
  5. National Science Foundation for Postdoctoral Scientists of China [2013T60939, 2012M521934]
  6. National Institute of Biomedical Imaging and Bioengineering (NIBIB), National Institutes of Health (NIH)

向作者/读者索取更多资源

The combination of hyperthermia and chemotherapy is able to greatly enhance the treatment efficacy mainly due to the synergistic interactions between these two treatments. In this study, we propose a new concept of mild hyperthermia enhanced chemotherapy to explore and validate the synergistic mechanism in vitro and in vivo. To do this, a novel kind of biodegradable nanotheranostics based on copper sulfide doped periodic mesoporous organosilica nanoparticles (CuS@PMOs) was constructed via an in situ growth method for light-triggered mild hyperthermia and drug delivery. The as-prepared CuS@PMOs exhibit a high doxorubicin (DOX) loading capacity of 470 mg/g. The DOX release from CuS@PMOs can be precisely controlled by three stimuli, including intracellular glutathione (GSH), acidic environment in tumor cells, and external laser irradiation. Most intriguingly, mild hyperthermia induced by laser-irradiated CuS nanoparticles can dramatically improve the cell uptake of nanotheranostics both in vitro and in vivo, thus significantly enhancing the chemotherapeutic efficacy for complete tumor growth suppression without recurrence. Meanwhile, the fluorescence recovery following the DOX release can be used as an indicator to monitor the chemotherapeutic progress. Published by Elsevier Ltd.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据